This is a non-interventional medical chart review study aiming to examine the effectiveness, safety, and treatment patterns of isavuconazole in 5 European countries (France, Germany, Italy, Spain, and United Kingdom). Eligible patients are adults who have been treated with isavuconazole in routine practice at participating sites since 15 October, 2015 or since the date of launch in the country if it is after 15 October, 2015 until 30 June, 2019. As this is an observational study, patients will be treated based on the standard of care at the discretion of their physician. No drugs will be supplied for this study and patients will receive treatment through standard local practice.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of Participants With Clinical Response at Week 6
Timeframe: Week 6 post index date (retrospective data extracted and evaluated from study start date and until study completion, approximately 34 months)
Number of Participants With Clinical Response at Week 12
Timeframe: Week 12 post index date (retrospective data extracted and evaluated from study start date and until study completion, approximately 34 months)
Number of Participants With Clinical Response at Week 24
Timeframe: Week 24 post index date (retrospective data extracted and evaluated from study start date and until study completion, approximately 34 months)
Number of Participants With Radiological Response at Week 6
Timeframe: Week 6 post index date or end of treatment, which ever occurred earlier (retrospective data extracted and evaluated from study start date and until study completion, approximately 34 months)
Number of Participants With Radiological Response at Week 12
Timeframe: Week 12 post index date or end of treatment, which ever occurred earlier (retrospective data extracted and evaluated from study start date and until study completion, approximately 34 months)
Number of Participants With Radiological Response at Week 24
Timeframe: Week 24 post index date or end of treatment, which ever occurred earlier (retrospective data extracted and evaluated from study start date and until study completion, approximately 34 months)
Number of Participants With Mycological Response at Week 6
Timeframe: Week 6 post index date (retrospective data extracted and evaluated from study start date and until study completion, approximately 34 months)
Number of Participants With Mycological Response at Week 12
Timeframe: Week 12 post index date (retrospective data extracted and evaluated from study start date and until study completion, approximately 34 months)
Number of Participants With Mycological Response at Week 24
Timeframe: Week 6 post index date (retrospective data extracted and evaluated from study start date and until study completion, approximately 34 months)
All-Cause Mortality at Week 6
Timeframe: Week 6 post index date (retrospective data extracted and evaluated from study start date and until study completion, approximately 34 months)
All-Cause Mortality at Week 12
Timeframe: Week 12 post index date (retrospective data extracted and evaluated from study start date and until study completion, approximately 34 months)
All-Cause Mortality at Week 24
Timeframe: Week 24 post index date (retrospective data extracted and evaluated from study start date and until study completion, approximately 34 months)
Number of Participants With Adverse Event at Week 6
Timeframe: Week 6 post index date (retrospective data extracted and evaluated from study start date and until study completion, approximately 34 months)
Number of Participants With Adverse Event at Week 12
Timeframe: Week 12 post index date (retrospective data extracted and evaluated from study start date and until study completion, approximately 34 months)
Number of Participants With Adverse Event at Week 24
Timeframe: Week 24 post index date (retrospective data extracted and evaluated from study start date and until study completion, approximately 34 months)
Number of Participants With Serious Adverse Event at Week 6
Timeframe: Week 6 post index date (retrospective data extracted and evaluated from study start date and until study completion, approximately 34 months)
Number of Participants With Serious Adverse Event at Week 12
Timeframe: Week 12 post index date (retrospective data extracted and evaluated from study start date and until study completion, approximately 34 months)
Number of Participants With Serious Adverse Event at Week 24
Timeframe: Week 24 post index date (retrospective data extracted and evaluated from study start date and until study completion, approximately 34 months)